InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Explore the complete record of transactions filed by ABERNETHY MATT, Chief Financial Officer. Officer active across 1 companies, notably Neurocrine Biosciences INC. Aggregated, 4 disclosures have been logged. Total volume traded: €526k. The latest transaction was filed on 7 February 2022 — Cession. Regulator: SEC (Form 4). All data is openly available.
Declarations4 total
€143,1952,030 shares@ €70.53950.0010% mcap54.4% of flow
Common Stock
SEC:0001209191-22-008203·
€143,1952,030 shares@ €70.53950.0010% mcap27.2% of flow
Common Stock
SEC:0001209191-22-008203:0·
€119,9021,645 shares@ €72.88880.0008% mcap45.6% of flow
Common Stock
SEC:0001209191-21-067870·
€119,9021,645 shares@ €72.88880.0008% mcap22.8% of flow
Common Stock
SEC:0001209191-21-067870:0·
4 of 4 declarations
About ABERNETHY MATT
Matt Abernethy is the Chief Financial Officer at Neurocrine Biosciences Inc. He is responsible for managing the company's finances, including financial planning, risk management, and regulatory compliance. His role is essential in ensuring the financial health and growth of the company.
